Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Basic Res Cardiol ; 110(2): 13, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25680868

ABSTRACT

Heart rupture and heart failure are deleterious complications of myocardial infarction. The ShcA gene encodes for three protein isoforms, p46-, p52- and p66ShcA. p66ShcA induces oxidative stress. We studied the role of p66ShcA post-infarction. Expression of p66ShcA was analyzed in myocardium of patients with stable angina (n = 11), in explanted hearts with end-stage ischemic heart failure (n = 9) and compared to non-failing hearts not suitable for donation (n = 7). p66ShcA was increased in the patients with stable angina, but not in the patients with end-stage heart failure. Mice (n = 105) were subjected to coronary artery ligation. p66ShcA expression and phosphorylation were evaluated over a 6-week period. p66ShcA expression increased transiently during the first weeks post-infarction. p66ShcA knockout mice (KO) were compared to wild type (n = 82 in total). KO had improved survival and reduced occurrence of heart rupture post-infarction. Expression of cardiac matrix metalloproteinase 2 (MMP-2) was reduced; fibroblast activation and collagen accumulation were facilitated, while oxidative stress was attenuated in KO early post-infarction. 6 weeks post-infarction, reactive fibrosis and left ventricular dilatation were diminished in KO. p66ShcA regulation of MMP-2 was demonstrated in cultured fibroblasts: lack or overexpression of p66ShcA in vitro altered expression of MMP-2. Myocardial infarction induced cardiac p66ShcA. Deletion of p66ShcA improved early survival, myocardial healing and reduced cardiac fibrosis. Upon myocardial infarction p66ShcA regulates MMP-2 activation. The role of p66ShcA in human cardiac disease deserves further study as a potential target for reducing adverse cardiac remodeling post-infarction.


Subject(s)
Myocardial Infarction/metabolism , Shc Signaling Adaptor Proteins/metabolism , Aged , Animals , Blotting, Western , Female , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Male , Matrix Metalloproteinase 2/biosynthesis , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Oxidative Stress/physiology , Real-Time Polymerase Chain Reaction , Src Homology 2 Domain-Containing, Transforming Protein 1 , Ventricular Remodeling/physiology
2.
Toxins (Basel) ; 4(12): 1427-39, 2012 Nov 30.
Article in English | MEDLINE | ID: mdl-23202375

ABSTRACT

The roles of immune cells and their soluble products during myocardial infarction (MI) are not completely understood. Here, we observed that the percentages of IL-17, but not IL-22, producing cells are reduced in mice splenocytes after developing MI. To correlate this finding with the functional activity of IL-17, we sought to determine its effect on monocytes. In particular, we presumed that this cytokine might affect the chemotaxis of monocytes important for cardiac inflammation and remodeling. We observed that IL-17 tends to reduce the expression of two major chemokine receptors involved in monocyte chemotaxis, namely CCR2 and CXCR4. Further analysis showed that monocytes pretreated with IL-17 have reduced in vitro chemotaxis towards the ligand for CCR2, i.e., MCP-1/CCL2, and the ligand for CXCR4, i.e., SDF-1α/CXCL12. Our results support the possibility that IL-17 may be beneficial in MI, and this could be due to its ability to inhibit the migration of monocytes.


Subject(s)
Chemokines/metabolism , Chemotaxis/drug effects , Interleukin-17/pharmacology , Monocytes/drug effects , Myocardial Infarction/metabolism , Animals , Interleukins/pharmacology , Male , Mice , Mice, Inbred C57BL , Monocytes/physiology , Receptors, CCR2/metabolism , Receptors, CXCR4/metabolism , Receptors, Interleukin/metabolism , Receptors, Interleukin-17/metabolism , Spleen/cytology , Interleukin-22
SELECTION OF CITATIONS
SEARCH DETAIL
...